Albany Molecular Research Other Current Liabilities

Albany Molecular Research posts a other current liabilities of $22M as of June 2017. That compares with $4.7M in the prior-year period — up 359.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Albany Molecular Research's other current liabilities was $4.7M. The latest reading is $22M — a 359.6% year-over-year increase (period ending June 2017). Use the history and growth charts on this page for a longer lookback.

Other Current Liabilities is one piece of Albany Molecular Research's financial statement story. At $22M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AMRI's other current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Albany Molecular Research's other metric pages and overview cover the third.